Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ENANTA PHARMACEUTICALS, INC Financing Cash Flow

ENANTA PHARMACEUTICALS, INC (ENTA) reported Financing Cash Flow of $51.30 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12

  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$5.54M.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$7.29M.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $64.14M.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$8.32M.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2025 was -$26.62M.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2024 was -$27.63M, a 113.94% decline from fiscal 2023.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2023 was $198.13M, a 889.00% increase from fiscal 2022.
  • ENANTA PHARMACEUTICALS, INC net cash provided by (used in) financing activities for fiscal 2022 was $20.03M, a 550.42% increase from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30-$5.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12
-$12.84M
derived: sum of 2 quarters · filed 2026-08-12
$51.30M
10-Q · filed 2026-08-12
$42.98M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$7.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13
$56.84M
10-Q · filed 2026-05-13
$48.52M
derived: sum of 3 quarters · filed 2026-05-13
$42.10M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$64.14M
10-Q · filed 2026-02-11
$55.81M
derived: sum of 2 quarters · filed 2026-02-11
$49.39M
derived: sum of 3 quarters · filed 2026-08-12
$42.50M
derived: sum of 4 quarters · filed 2026-08-12
2025-09-30-$8.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
-$14.74M
derived: sum of 2 quarters · filed 2026-08-12
-$21.63M
derived: sum of 3 quarters · filed 2026-08-12
-$26.62M
10-K · filed 2025-11-19
2025-06-30-$6.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12
-$13.31M
derived: sum of 2 quarters · filed 2026-08-12
-$18.30M
10-Q · filed 2026-08-12
-$25.51M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$6.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-13
-$11.87M
10-Q · filed 2026-05-13
-$19.09M
derived: sum of 3 quarters · filed 2026-05-13
-$25.73M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$4.99M
10-Q · filed 2026-02-11
-$12.20M
derived: sum of 2 quarters · filed 2026-02-11
-$18.85M
derived: sum of 3 quarters · filed 2026-02-11
-$25.26M
derived: sum of 4 quarters · filed 2026-02-11
2024-09-30-$7.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
-$13.86M
derived: sum of 2 quarters · filed 2025-11-19
-$20.28M
derived: sum of 3 quarters · filed 2025-11-19
-$27.63M
10-K · filed 2025-11-19
2024-06-30-$6.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13
-$13.06M
derived: sum of 2 quarters · filed 2025-08-13
-$20.41M
10-Q · filed 2025-08-13
-$20.43M
derived: sum of 4 quarters · filed 2025-11-19
2024-03-31-$6.41M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14
-$13.76M
10-Q · filed 2025-05-14
-$13.79M
derived: sum of 3 quarters · filed 2025-11-19
$186.09M
derived: sum of 4 quarters · filed 2025-11-19
2023-12-31-$7.35M
10-Q · filed 2025-02-12
-$7.37M
derived: sum of 2 quarters · filed 2025-11-19
$192.50M
derived: sum of 3 quarters · filed 2025-11-19
$190.47M
derived: sum of 4 quarters · filed 2025-11-19
2023-09-30-$23.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
$199.85M
derived: sum of 2 quarters · filed 2025-11-19
$197.82M
derived: sum of 3 quarters · filed 2025-11-19
$198.13M
10-K · filed 2025-11-19
2023-06-30$199.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07
$197.85M
derived: sum of 2 quarters · filed 2024-08-07
$198.15M
10-Q · filed 2024-08-07
$201.08M
derived: sum of 4 quarters · filed 2024-11-27
2023-03-31-$2.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08
-$1.73M
10-Q · filed 2024-05-08
$1.20M
derived: sum of 3 quarters · filed 2024-11-27
$5.32M
derived: sum of 4 quarters · filed 2024-11-27
2022-12-31$301.00K
10-Q · filed 2024-02-08
$3.23M
derived: sum of 2 quarters · filed 2024-11-27
$7.35M
derived: sum of 3 quarters · filed 2024-11-27
$10.70M
derived: sum of 4 quarters · filed 2024-11-27
2022-09-30$2.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27
$7.05M
derived: sum of 2 quarters · filed 2024-11-27
$10.40M
derived: sum of 3 quarters · filed 2024-11-27
$20.03M
10-K · filed 2024-11-27
2022-06-30$4.12M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08
$7.47M
derived: sum of 2 quarters · filed 2023-08-08
$17.10M
10-Q · filed 2023-08-08
$18.05M
derived: sum of 4 quarters · filed 2023-11-22
2022-03-31$3.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-09
$12.98M
10-Q · filed 2023-05-09
$13.93M
derived: sum of 3 quarters · filed 2023-11-22
$14.61M
derived: sum of 4 quarters · filed 2023-11-22
2021-12-31$9.63M
10-Q · filed 2023-02-08
$10.57M
derived: sum of 2 quarters · filed 2023-11-22
$11.26M
derived: sum of 3 quarters · filed 2023-11-22
$12.41M
derived: sum of 4 quarters · filed 2023-11-22
2021-09-30$943.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22
$1.63M
derived: sum of 2 quarters · filed 2023-11-22
$2.78M
derived: sum of 3 quarters · filed 2023-11-22
$3.08M
10-K · filed 2023-11-22
2021-06-30$686.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08
$1.84M
derived: sum of 2 quarters · filed 2022-08-08
$2.14M
10-Q · filed 2022-08-08
$2.37M
derived: sum of 4 quarters · filed 2022-11-23
2021-03-31$1.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09
$1.45M
10-Q · filed 2022-05-09
$1.68M
derived: sum of 3 quarters · filed 2022-11-23
$4.91M
derived: sum of 4 quarters · filed 2022-11-23
2020-12-31$299.00K
10-Q · filed 2022-02-10
$532.00K
derived: sum of 2 quarters · filed 2022-11-23
$3.76M
derived: sum of 3 quarters · filed 2022-11-23
$8.12M
derived: sum of 4 quarters · filed 2022-11-23
2020-09-30$233.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23
$3.46M
derived: sum of 2 quarters · filed 2022-11-23
$7.82M
derived: sum of 3 quarters · filed 2022-11-23
$8.98M
10-K · filed 2022-11-23
2020-06-30$3.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09
$7.58M
derived: sum of 2 quarters · filed 2021-08-09
$8.75M
10-Q · filed 2021-08-09
$9.44M
derived: sum of 4 quarters · filed 2021-11-24
2020-03-31$4.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-10
$5.52M
10-Q · filed 2021-05-10
$6.21M
derived: sum of 3 quarters · filed 2021-11-24
$6.70M
derived: sum of 4 quarters · filed 2021-11-24
2019-12-31$1.17M
10-Q · filed 2021-02-09
$1.85M
derived: sum of 2 quarters · filed 2021-11-24
$2.34M
derived: sum of 3 quarters · filed 2021-11-24
$2.60M
derived: sum of 4 quarters · filed 2021-11-24
2019-09-30$687.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24
$1.18M
derived: sum of 2 quarters · filed 2021-11-24
$1.43M
derived: sum of 3 quarters · filed 2021-11-24
$2.57M
10-K · filed 2021-11-24
2019-06-30$490.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10
$747.00K
derived: sum of 2 quarters · filed 2020-08-10
$1.89M
10-Q · filed 2020-08-10
$2.92M
derived: sum of 4 quarters · filed 2020-11-25
2019-03-31$257.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11
$1.40M
10-Q · filed 2020-05-11
$2.43M
derived: sum of 3 quarters · filed 2020-11-25
$5.39M
derived: sum of 4 quarters · filed 2020-11-25
2018-12-31$1.14M
10-Q · filed 2020-02-10
$2.17M
derived: sum of 2 quarters · filed 2020-11-25
$5.14M
derived: sum of 3 quarters · filed 2020-11-25
$5.13M
derived: sum of 4 quarters · filed 2020-11-25
2018-09-30$1.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25
$4.00M
derived: sum of 2 quarters · filed 2020-11-25
$3.99M
derived: sum of 3 quarters · filed 2020-11-25
$4.41M
10-K · filed 2020-11-25
2018-06-30$2.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09
$2.96M
derived: sum of 2 quarters · filed 2019-08-09
$3.38M
10-Q · filed 2019-08-09
$4.38M
derived: sum of 4 quarters · filed 2019-11-27
2018-03-31-$6.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10
$411.00K
10-Q · filed 2019-05-10
$1.42M
derived: sum of 3 quarters · filed 2019-11-27
2017-12-31$417.00K
10-Q · filed 2019-02-08
$1.42M
derived: sum of 2 quarters · filed 2019-11-27
2017-09-30$1.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
$1.02M
10-K · filed 2019-11-27
2017-06-30$10.00K
10-Q · filed 2018-08-09
2016-09-30$2.71M
10-K · filed 2018-11-29
2014-03-31$557.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12
$646.00K
10-Q · filed 2014-05-12
$768.00K
derived: sum of 3 quarters · filed 2014-05-12
-$677.00K
derived: sum of 4 quarters · filed 2014-05-12
2013-12-31$89.00K
10-Q · filed 2014-02-13
$211.00K
derived: sum of 2 quarters · filed 2014-02-13
-$1.23M
derived: sum of 3 quarters · filed 2014-02-13
$58.32M
derived: sum of 4 quarters · filed 2014-05-12
2013-09-30$122.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18
-$1.32M
derived: sum of 2 quarters · filed 2013-12-18
$58.23M
derived: sum of 3 quarters · filed 2014-05-12
$56.91M
10-K · filed 2013-12-18
2013-06-30-$1.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12
$58.11M
derived: sum of 2 quarters · filed 2014-05-12
$56.79M
10-Q · filed 2013-08-12
$55.80M
derived: sum of 4 quarters · filed 2014-05-12
2013-03-31$59.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-12
$58.23M
10-Q · filed 2014-05-12
$57.24M
derived: sum of 3 quarters · filed 2014-05-12
$57.22M
derived: sum of 4 quarters · filed 2014-05-12
2012-12-31-$1.32M
10-Q · filed 2014-02-13
-$2.31M
derived: sum of 2 quarters · filed 2014-02-13
-$2.34M
derived: sum of 3 quarters · filed 2014-02-13
2012-09-30-$991.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-18
-$1.02M
derived: sum of 2 quarters · filed 2013-12-18
-$909.00K
10-K · filed 2013-12-18
2012-06-30-$25.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-12
$82.00K
10-Q · filed 2013-08-12
2012-03-31$107.00K
10-Q · filed 2013-05-15
2011-09-30$34.00K
10-K · filed 2013-12-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63